Genocea Biosciences (GNCA)

Genocea Biosciences (GNCA) Income Statement


Genocea Biosciences Income Statement

Last quarter (Q ), Genocea Biosciences's total revenue was $270.00K, an increase of Infinity% from the same quarter last year. In Q, Genocea Biosciences's net income was $-15.98M. See Genocea Biosciences’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
$ 1.91M$ 1.64M$ 1.36M$ 0.00$ 0.00$ 0.00
Cost of Revenue
Gross Profit
Operating Expense
$ 57.35M$ 53.73M$ 48.35M$ 38.99M$ 39.52M$ 52.64M
Operating Income
$ -55.44M$ -52.09M$ -46.99M$ -38.99M$ -39.52M$ -52.64M
Net Non Operating Interest Income Expense
$ -1.07M$ -1.12M$ -1.38M$ -946.00K$ -1.02M$ -1.44M
Other Income Expense
$ 19.33M$ 20.02M$ 4.66M$ 985.00K$ 12.73M$ -2.63M
Pretax Income
$ -37.19M$ -33.20M$ -43.71M$ -38.95M$ -27.81M$ -56.71M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -37.19M$ -33.20M$ -43.71M$ -38.95M$ -27.81M$ -56.71M
Basic EPS
$ -0.52$ -0.48$ -0.98$ -1.89$ -2.69$ -15.84
Diluted EPS
$ -0.66$ -0.48$ -1.11$ -1.89$ -2.69$ -15.84
Basic Average Shares
$ 279.20M$ 68.58M$ 44.44M$ 20.64M$ 10.32M$ 3.58M
Diluted Average Shares
$ 281.44M$ 68.58M$ 46.55M$ 20.64M$ 10.32M$ 3.58M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 57.35M$ 53.73M$ 48.35M$ 38.99M$ 39.52M$ 52.64M
Net Income From Continuing And Discontinued Operation
$ -37.19M$ -33.20M$ -43.71M$ -38.95M$ -27.81M$ -56.71M
Normalized Income
$ -56.49M$ -53.34M$ -52.60M$ -39.94M$ -42.57M$ -54.09M
Interest Expense
$ 1.07M$ 1.12M$ 1.38M$ 946.00K$ 1.02M$ 1.44M
$ -36.12M$ -32.08M$ -42.33M$ -38.00M$ -26.79M$ -55.27M
$ -34.54M$ -30.52M$ -41.20M$ -36.91M$ -25.70M$ -53.75M
Currency in USD

Genocea Biosciences Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis